V&W Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 02-11-2024
- Paid Up Capital ₹ 0.10 M
as on 02-11-2024
- Company Age 3 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.60 Cr
as on 02-11-2024
- Revenue 7495.94%
(FY 2023)
- Profit 1213.67%
(FY 2023)
- Ebitda 52.77%
(FY 2023)
- Net Worth 1225.84%
(FY 2023)
- Total Assets 959.82%
(FY 2023)
About V&W Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.60 Cr.
Preshit Wagh, Sandeep Vanjari, Ganapathy Kumar, and One other member serve as directors at the Company.
- CIN/LLPIN
U29297PN2021PTC205270
- Company No.
205270
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Oct 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at V&W Biotech?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sandeep Vanjari  | Director | 18-Oct-2021 | Current |
| Preshit Wagh | Director | 18-Oct-2021 | Current |
| Ganapathy Kumar | Director | 18-Oct-2021 | Current |
| Swapnil Vanjari | Director | 18-Oct-2021 | Current |
Financial Performance of V&W Biotech.
V&W Biotech Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 7495.94% increase. The company also saw a substantial improvement in profitability, with a 1213.67% increase in profit. The company's net worth Soared by an impressive increase of 1225.84%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of V&W Biotech?
Unlock access to V&W Biotech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 11 May 2023 | ₹4.60 Cr | Open |
How Many Employees Work at V&W Biotech?
V&W Biotech has a workforce of 0 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of V&W Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped V&W Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
